Extracellular adenosine-mediated modulation of regulatory T cells

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Ohta, Akio ^a   Sitkovsky, Michail ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

A2A adenosine receptor; A2B adenosine receptor; Adenosine; Immunosuppression; Regulatory T cell; Tumor microenvironment

Indexed keywords

EID: 84905657094     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00304     Document Type: Review

References (111)

1. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 25:267-96. doi: 10.1146/annurev.immunol.25.022106.141609
2. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 8:74-80. doi:10.1038/nri2233
3. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 224:166-82. doi:10.1111/j.1600-065X.2008.00662.x
4. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 14:1212-8. doi:10.1038/ni.2762
5. Fredholm BB, Ap IJ, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 53:527-52.
6. Fredholm BB, Ap IJ, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update. Pharmacol Rev (2011) 63:1-34. doi:10.1124/pr.110.003285
7. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med (2012) 367:2322-33. doi:10.1056/NEJMra1205750
8. Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets - what are the challenges? Nat Rev Drug Discov (2013) 12:265-86. doi:10.1038/nrd3955
9. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol (2004) 22:657-82. doi:10.1146/annurev.immunol.22.012703.104731
10. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature (2001) 414:916-20. doi:10.1038/414916a
11. Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P, et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol (2005) 3:e174. doi:10.1371/journal.pbio.0030174
12. Mohsenin A, Mi T, Xia Y, Kellems RE, Chen JF, Blackburn MR. Genetic removal of the A2A adenosine receptor enhances pulmonary inflammation, mucin production, and angiogenesis in adenosine deaminase-deficient mice. Am J Physiol Lung Cell Mol Physiol (2007) 293:L753-61. doi:10.1152/ajplung.00187.2007
13. Nadeem A, Fan M, Ansari HR, Ledent C, Jamal Mustafa S. Enhanced airway reactivity and inflammation in A2A adenosine receptor-deficient allergic mice. Am J Physiol Lung Cell Mol Physiol (2007) 292:L1335-44. doi:10.1152/ajplung.00416.2006
14. Alam MS, Kurtz CC, Wilson JM, Burnette BR, Wiznerowicz EB, Ross WG, et al. A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol (2009) 2:232-42. doi:10.1038/mi.2009.4
15. Karhausen J, Haase VH, Colgan SP. Inflammatory hypoxia: role of hypoxia-inducible factor. Cell Cycle (2005) 4:256-8. doi:10.4161/cc.4.2.1407
16. Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P. A(2B) adenosine receptors in immunity and inflammation. Trends Immunol (2009) 30:263-70. doi:10.1016/j.it.2009.04.001
17. Koeppen M, Eckle T, Eltzschig HK. Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol (2011) 61:145-86. doi:10.1016/B978-0-12-385526-8.00006-0
18. Ben Addi A, Lefort A, Hua X, Libert F, Communi D, Ledent C, et al. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol (2008) 38:1610-20. doi:10.1002/eji.200737781
19. Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood (2008) 112:1822-31. doi:10.1182/blood-2008-02-136325
20. Volmer JB, Thompson LF, Blackburn MR. Ecto-5′ -nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol (2006) 176:4449-58. doi:10.4049/jimmunol.176.7.4449
21. Grenz A, Zhang H, Weingart J, Von Wietersheim S, Eckle T, Schnermann J, et al. Lack of effect of extracellular adenosine generation and signaling on renal erythropoietin secretion during hypoxia. Am J Physiol Renal Physiol (2007) 293:F1501-11. doi:10.1152/ajprenal.00243.2007
22. Resta R, Hooker SW, Laurent AB, Jamshedur Rahman SM, Franklin M, Knudsen TB, et al. Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto-5′ -nucleotidase (CD73). J Clin Invest (1997) 99:676-83. doi:10.1172/JCI119211
23. Tofovic SP, Zacharia L, Carcillo JA, Jackson EK. Inhibition of adenosine deaminase attenuates endotoxin-induced release of cytokines in vivo in rats. Shock (2001) 16:196-202. doi:10.1097/00024382-200116030-00005
24. Driver AG, Kukoly CA, Ali S, Mustafa SJ. Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis (1993) 148:91-7. doi:10.1164/ajrccm/148.1.91
25. Nishiyama A, Miura K, Miyatake A, Fujisawa Y, Yue W, Fukui T, et al. Renal interstitial concentration of adenosine during endotoxin shock. Eur J Pharmacol (1999) 385:209-16. doi:10.1016/S0014-2999(99)00716-5
26. Martin C, Leone M, Viviand X, Ayem ML, Guieu R. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med (2000) 28:3198-202. doi:10.1097/00003246-200009000-00014
27. Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil-derived 5′ -adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med (1998) 188:1433-43. doi:10.1084/jem.188.8.1433
28. Mizumoto N, Kumamoto T, Robson SC, Sevigny J, Matsue H, Enjyoji K, et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med (2002) 8:358-65. doi:10.1038/nm0402-358
29. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-5′ -nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest (2002) 110:993-1002. doi:10.1172/JCI0215337
30. Deaglio S, Robson SC. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol (2011) 61:301-32. doi:10.1016/B978-0-12-385526-8.00010-2
31. Kobayashi S, Zimmermann H, Millhorn DE. Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. J Neurochem (2000) 74:621-32. doi:10.1046/j.1471-4159.2000.740621.x
32. Morote-Garcia JC, Rosenberger P, Kuhlicke J, Eltzschig HK. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood (2008) 111:5571-80. doi:10.1182/blood-2007-11-126763
33. Narravula S, Lennon PF, Mueller BU, Colgan SP. Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function. J Immunol (2000) 165:5262-8. doi:10.4049/jimmunol.165.9.5262
34. Eckle T, Fullbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, et al. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol (2007) 178:8127-37. doi:10.4049/jimmunol.178.12.8127
35. Louis NA, Robinson AM, MacManus CF, Karhausen J, Scully M, Colgan SP. Control of IFN-alphaA by CD73: implications for mucosal inflammation. J Immunol (2008) 180:4246-55. doi:10.4049/jimmunol.180.6.4246
36. Ohtsuka T, Changelian PS, Bouis D, Noon K, Harada H, Lama VN, et al. Ecto-5′ -nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation. J Immunol (2010) 185:1321-9. doi:10.4049/jimmunol.0901847
37. Tsukamoto H, Chernogorova P, Ayata K, Gerlach UV, Rughani A, Ritchey JW, et al. Deficiency of CD73/ecto-5′ -nucleotidase in mice enhances acute graft-versus-host disease. Blood (2012) 119:4554-64. doi:10.1182/blood-2011-09-375899
38. Jarvis MF, Yu H, McGaraughty S, Wismer CT, Mikusa J, Zhu C, et al. Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor. Pain (2002) 96:107-18. doi:10.1016/S0304-3959(01)00435-3
39. Laghi-Pasini F, Guideri F, Petersen C, Lazzerini PE, Sicari R, Capecchi PL, et al. Blunted increase in plasma adenosine levels following dipyridamole stress in dilated cardiomyopathy patients. J Intern Med (2003) 254:591-6. doi:10.1111/j.1365-2796.2003.01234.x
40. Rudensky AY. Regulatory T cells Foxp3. Immunol Rev (2011) 241:260-8. doi:10.1111/j.1600-065X.2011.01018.x
41. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity (2013) 38:414-23. doi:10.1016/j.immuni.2013.03.002
42. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol (2010) 185:1993-8. doi:10.4049/jimmunol.1000108
43. Whiteside TL, Jackson EK. Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol (2013) 4:212. doi:10.3389/fimmu.2013.00212
44. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′ -adenosine monophosphate to adenosine. J Immunol (2006) 177:6780-6. doi:10.4049/jimmunol.177.10.6780
45. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 204:1257-65. doi:10.1084/jem.20062512
46. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 15:6348-57. doi:10.1158/1078-0432.CCR-09-1143
47. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2010) 285:7176-86. doi:10.1074/jbc.M109.047423
48. Kinsey GR, Huang L, Jaworska K, Khutsishvili K, Becker DA, Ye H, et al. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol (2012) 23:1528-37. doi:10.1681/ASN.2012010070
49. Hesdorffer CS, Malchinkhuu E, Biragyn A, Mabrouk OS, Kennedy RT, Madara K, et al. Distinctive immunoregulatory effects of adenosine on T cells of older humans. FASEB J (2012) 26:1301-10. doi:10.1096/fj.11-197046
50. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med (2007) 204:1303-10. doi:10.1084/jem.20062129
51. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity (2008) 29:771-81. doi:10.1016/j.immuni.2008.08.018
52. Yaqub S, Tasken K. Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit Rev Oncog (2008) 14:57-77. doi:10.1615/CritRevOncog.v14.i1.40
53. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Jackson EK, Johnson JT, et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 285:27571-80. doi:10.1074/jbc.M110.127100
54. Ehrentraut H, Clambey ET, McNamee EN, Brodsky KS, Ehrentraut SF, Poth JM, et al. CD73+ regulatory T cells contribute to adenosine-mediated resolution of acute lung injury. FASEB J (2013) 27:2207-19. doi:10.1096/fj.12-225201
55. Wang L, Fan J, Chen S, Zhang Y, Curiel TJ, Zhang B. Graft-versus-host disease is enhanced by selective CD73 blockade in mice. PLoS One (2013) 8:e58397. doi:10.1371/journal.pone.0058397
56. Ring S, Oliver SJ, Cronstein BN, Enk AH, Mahnke K. CD4+CD25+ regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. J Allergy Clin Immunol (2009) 123(1287-1296):e1282. doi:10.1016/j.jaci.2009.03.022
57. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kok A, et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog (2011) 7:e1002110. doi:10.1371/journal.ppat.1002110
58. Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, Ernst PB. Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol (2006) 177:2765-9. doi:10.4049/jimmunol.177.5.2765
59. Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression re-direction of the immune response. Trends Immunol (2009) 30:102-8. doi:10.1016/j.it.2008.12.002
60. Ben-Shoshan J, Maysel-Auslender S, Mor A, Keren G, George J. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1 alpha. Eur J Immunol (2008) 38:2412-8. doi:10.1002/eji.200838318
61. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 146:772-84. doi:10.1016/j.cell.2011.07.033
62. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 208:1367-76. doi:10.1084/jem.20110278
63. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A (2012) 109:E2784-93. doi:10.1073/pnas.1202366109
64. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol (2012) 3:190. doi:10.3389/fimmu.2012.00190
65. Han KL, Thomas SV, Koontz SM, Changpriroa CM, Ha SK, Malech HL, et al. Adenosine A(2)A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease. J Immunol (2013) 190:458-68. doi:10.4049/jimmunol.1201325
66. Lee DJ, Taylor AW. Both MC5r and A2Ar are required for protective regulatory immunity in the spleen of post-experimental autoimmune uveitis in mice. J Immunol (2013) 191:4103-11. doi:10.4049/jimmunol.1300182
67. Becker C, Taube C, Bopp T, Becker C, Michel K, Kubach J, et al. Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells. Blood (2009) 114:1263-9. doi:10.1182/blood-2009-02-206730
68. Guereschi MG, Araujo LP, Maricato JT, Takenaka MC, Nascimento VM, Vivanco BC, et al. Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner. Eur J Immunol (2013) 43:1001-12. doi:10.1002/eji.201243005
69. Bodor J, Bopp T, Vaeth M, Klein M, Serfling E, Hunig T, et al. Cyclic AMP underpins suppression by regulatory T cells. Eur J Immunol (2012) 42:1375-84. doi:10.1002/eji.201141578
70. Klein M, Vaeth M, Scheel T, Grabbe S, Baumgrass R, Berberich-Siebelt F, et al. Repression of cyclic adenosine monophosphate upregulation disarms and expands human regulatory T cells. J Immunol (2012) 188:1091-7. doi:10.4049/jimmunol.1102045
71. Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, et al. Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res (2013) 73:5647-56. doi:10.1158/0008-5472.CAN-12-3788
72. Cadieux JS, Leclerc P, St-Onge M, Dussault AA, Lafl Amme C, Picard S, et al. Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci (2005) 118:1437-47. doi:10.1242/jcs.01737
73. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2008) 111:251-9. doi:10.1182/blood-2007-03-081646
74. Ehrentraut H, Westrich JA, Eltzschig HK, Clambey ET. Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation. PLoS One (2012) 7:e32416. doi:10.1371/journal.pone.0032416
75. Pozo D, Anderson P, Gonzalez-Rey E. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol (2009) 183:4346-59. doi:10.4049/jimmunol.0900400
76. Sauer AV, Brigida I, Carriglio N, Hernandez RJ, Scaramuzza S, Clavenna D, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood (2012) 119:1428-39. doi:10.1182/blood-2011-07-366781
77. Regateiro FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold SP, et al. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-beta. Eur J Immunol (2011) 41:2955-65. doi:10.1002/eji.201141512
78. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, et al. Methotrexate - how does it really work? Nat Rev Rheumatol (2010) 6:175-8. doi:10.1038/nrrheum.2010.5
79. Carneiro-Ramos MS, Da Silva VB, Coutinho MB Jr, Battastini AM, Sarkis JJ, Barreto-Chaves ML. Thyroid hormone stimulates 5′ -ecto-nucleotidase of neonatal rat ventricular myocytes. Mol Cell Biochem (2004) 265:195-201. doi:10.1023/B:MCBI.0000044396.31443.a8
80. Niemela J, Henttinen T, Yegutkin GG, Airas L, Kujari AM, Rajala P, et al. IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5′ -nucleotidase) up-regulation. J Immunol (2004) 172:1646-53. doi:10.4049/jimmunol.172.3.1646
81. Bernardi A, Bavaresco L, Wink MR, Jacques-Silva MC, Delgado-Canedo A, Lenz G, et al. Indomethacin stimulates activity and expression of ecto-5′ -nucleotidase/CD73 in glioma cell lines. Eur J Pharmacol (2007) 569:8-15. doi:10.1016/j.ejphar.2007.04.058
82. Meijer P, Oyen WJ, Dekker D, Van Den Broek PH, Wouters CW, Boerman OC, et al. Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol (2009) 29:963-8. doi:10.1161/ATVBAHA.108.179622
83. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum (2000) 43:656-63. doi:10.1002/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H
84. Chan ES, Cronstein BN. Methotrexate - how does it really work? Nat Rev Rheumatol (2010) 6:175-8. doi:10.1038/nrrheum.2010.5
85. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol (1996) 156:1937-41.
86. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′ -nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest (1998) 101:295-300. doi:10.1172/JCI1554
87. Kim YC, Kim KK, Shevach EM. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction. Immunology (2010) 130:484-93. doi:10.1111/j.1365-2567.2010.03269.x
88. Tang TT, Song Y, Ding YJ, Liao YH, Yu X, Du R, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res (2011) 52:1023-32. doi:10.1194/jlr.M010876
89. Hilbrands R, Howie D, Cobbold S, Waldmann H. Regulatory T cells and transplantation tolerance. Immunotherapy (2013) 5:717-31. doi:10.2217/imt.13.69
90. Singer BD, King LS, D'Alessio FR. Regulatory T cells as immunotherapy. Front Immunol (2014) 5:46. doi:10.3389/fimmu.2014.00046
91. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 12:443-58. doi:10.1038/nri3212
92. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 72:3125-30. doi:10.1158/0008-5472.CAN-11-4094
93. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res (1997) 57:2602-5.
94. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 103:13132-7. doi:10.1073/pnas.0605251103
95. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer (2004) 4:437-47. doi:10.1038/nrc1367
96. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 26:225-39. doi:10.1007/s10555-007-9055-1
97. Ryzhov S, Novitskiy SV, Zaynagetdinov R, Goldstein AE, Carbone DP, Biaggioni I, et al. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia (2008) 10:987-95. doi:10.1593/neo.08478
98. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2012) 188:198-205. doi:10.4049/jimmunol.1101845
99. Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res (2010) 70:6407-11. doi:10.1158/0008-5472.CAN-10-1544
100. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 33:231-7. doi:10.1016/j.it.2012.02.009
101. Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I, et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol (2011) 187:6120-9. doi:10.4049/jimmunol.1101225
102. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 70:2245-55. doi:10.1158/0008-5472.CAN-09-3109
103. Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother (2012) 61:917-26. doi:10.1007/s00262-011-1155-7
104. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 107:1547-52. doi:10.1073/pnas.0908801107
105. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood (1997) 90:1600-10.
106. Sevigny CP, Li L, Awad AS, Huang L, McDuffie M, Linden J, et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol (2007) 178:4240-9. doi:10.4049/jimmunol.178.7.4240
107. Linnemann C, Schildberg FA, Schurich A, Diehl L, Hegenbarth SI, Endl E, et al. Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology (2009) 128:e728-37. doi:10.1111/j.1365-2567.2009.03075.x
108. Raskovalova T, Lokshin A, Huang X, Su Y, Mandic M, Zarour HM, et al. Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res (2007) 67:5949-56. doi:10.1158/0008-5472.CAN-06-4249
109. Ohta A, Ohta A, Madasu M, Kini R, Subramanian M, Goel N, et al. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol (2009) 183:5487-93. doi:10.4049/jimmunol.0901247
110. Hofer S, Ivarsson L, Stoitzner P, Auffinger M, Rainer C, Romani N, et al. Adenosine slows migration of dendritic cells but does not affect other aspects of dendritic cell maturation. J Invest Dermatol (2003) 121:300-7. doi:10.1046/j.1523-1747.2003.12369.x
111. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 7:759-70. doi:10.1038/nrd2638